Health-related quality of life in survivors of septic shock: 6-month follow-up from the ADRENAL trial

Research output: Contribution to journalJournal articleResearchpeer-review

  • Naomi E. Hammond
  • Simon R. Finfer
  • Qiang Li
  • Colman Taylor
  • Jeremy Cohen
  • Yaseen Arabi
  • Rinaldo Bellomo
  • Laurent Billot
  • Meg Harward
  • Christopher Joyce
  • Colin McArthur
  • John Myburgh
  • Perner, Anders
  • Dorrilyn Rajbhandari
  • Andrew Rhodes
  • Kelly Thompson
  • Steve Webb
  • Balasubramanian Venkatesh
  • Keri Anne Cowdrey
  • Eileen Gilder
  • Stephanie Long
  • Lianne McCarthy
  • Shay McGuinness
  • Rachael Parke
  • Kristen Benefield
  • Yan Chen
  • Rachael McConnochie
  • Lynette Newby
  • Glenn Eastwood
  • Daryl Jones
  • Leah Peck
  • Helen Young
  • Catherine Boschert
  • John Edington
  • Jason Fletcher
  • Julie Smith
  • Dhaval Ghelani
  • Kiran Nand
  • Graham Reece
  • Treena Sara
  • Jeremy Bewley
  • Libby Cole
  • Maj Brit Nørregaard Kjær
  • Martin Bruun Madsen
  • Møller, Morten Hylander
  • Rasmus Müller
  • Jonas Nielsen
  • Lars Quist
  • Hans Christian Thorsen-Meyer
  • Jonathan White
  • the ADRENAL Trial Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group

Purpose: To investigate the impact of hydrocortisone treatment and illness severity on health-related quality of life (HRQoL) at 6 months in septic shock survivors from the ADRENAL trial. Methods: Using the EuroQol questionnaire (EQ-5D-5L) at 6 months after randomization we assessed HRQoL in patient subgroups defined by hydrocortisone or placebo treatment, gender, illness severity (APACHE II < or ≥ 25), and severity of shock (baseline peak catecholamine doses < or ≥ 15 mcg/min). Additionally, in subgroups defined by post-randomisation variables; time to shock reversal (days), treatment with renal replacement therapy (RRT), and presence of bacteremia. Results: At 6 months, there were 2521 survivors. Of these 2151 patients (85.3%-1080 hydrocortisone and 1071 placebo) completed 6-month follow-up. Overall, at 6 months the mean EQ-5D-5L visual analogue scale (VAS) was 70.8, mean utility score 59.4. Between 15% and 30% of patients reported moderate to severe problems in any given HRQoL domain. There were no differences in any EQ-5D-5L domain in patients who received hydrocortisone vs. placebo, nor in the mean VAS (p = 0.6161), or mean utility score (p = 0.7611). In all patients combined, males experienced lower pain levels compared to females [p = 0.0002). Neither higher severity of illness or shock impacted reported HRQoL. In post-randomisation subgroups, longer time to shock reversal was associated with increased problems with mobility (p = < 0.0001]; self-care (p = 0.0.0142), usual activities (p = <0.0001] and pain (p = 0.0384). Amongst those treated with RRT, more patients reported increased problems with mobility (p = 0.0307) and usual activities (p = 0.0048) compared to those not treated. Bacteraemia was not associated with worse HRQoL in any domains of the EQ-5D-5L. Conclusions: Approximately one fifth of septic shock survivors report moderate to extreme problems in HRQoL domains at 6 months. Hydrocortisone treatment for septic shock was not associated with improved HRQoL at 6 months. Female gender was associated with worse pain at 6 months.

Original languageEnglish
JournalIntensive Care Medicine
Volume46
Issue number9
Pages (from-to)1696-1706
Number of pages11
ISSN0342-4642
DOIs
Publication statusPublished - 2020

    Research areas

  • EQ5D, Health-related quality of life, Intensive care, Sepsis, Septic shock, Steroids

ID: 260298793